News
JNJ-1900 (NBTXR3), a novel, potentially first-in-class oncology therapy, demonstrated a median overall survival of 23 months ...
A Phase III randomized trial published in JAMA Network Open found no significant difference in symptom improvement between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback